安进Amgen（AMGN）2025年第二季度业绩报告「NASDAQ」（英文版）（24页）.pdf

1、News ReleaseOne Amgen Center DriveThousand Oaks,CA 91320-1799Telephone 805-447-AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTSTHOUSAND OAKS,Calif.(Aug.5,2025)-Amgen(NASDAQ:AMGN)today announced financial results for the second quarter of 2025.“Were delivering strong performance and reaching more

2、patients with innovative medicines and biosimilars that address serious diseases.We continue to invest in science that enables longer,healthier lives and supports sustainable,long-term growth,”said Robert A.Bradway,chairman and chief executive officer.Key results include:For the second quarter,total

3、 revenues increased 9%to$9.2 billion in comparison to thesecond quarter of 2024.Product sales grew 9%,driven by 13%volume growth,partially offset by 3%lower netselling price.Fifteen products delivered at least double-digit sales growth in the second quarter,including Repatha(evolocumab),EVENITY(romo

4、sozumab-aqqg),IMDELLTRA(tarlatamab-dlle)/IMDYLLTRA(tarlatamab),BLINCYTO(blinatumomab),TEZSPIRE(tezepelumab-ekko),UPLIZNA(inebilizumab-cdon),and TAVNEOS(avacopan).GAAP earnings per share(EPS)increased 92%from$1.38 to$2.65,primarily driven byhigher revenues.GAAP operating income increased from$1.9 bil

5、lion to$2.7 billion,and GAAPoperating margin increased 6.6 percentage points to 30.3%.Non-GAAP EPS increased 21%from$4.97 to$6.02,primarily driven by higher revenues,partially offset by higher operating expenses.Non-GAAP operating income increased from$3.9 billion to$4.3 billion,and non-GAAPoperatin

6、g margin increased 0.7 percentage points to 48.9%.The Company generated$1.9 billion of free cash flow in the second quarter of 2025versus$2.2 billion in the second quarter of 2024,driven by 2024 tax payments deferred to2025 and higher capital expenditures,partially offset by business performance.Ref